文献速递肝胆胰外科围术期管理与 ERAS

新辅助治疗后低淋巴细胞单核细胞比值预测交界可切除胰腺癌胰腺切除术后生存不良

Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
PubMed 文献 · Surgery · 2019-02-11

该回顾性研究纳入67例接受新辅助治疗后行胰腺切除的交界可切除胰腺癌患者,并与58例直接手术者比较,评估新辅助治疗后系统性免疫炎症标志物对生存的预测价值。多因素分析显示新辅助治疗后淋巴细胞单核细胞比值<3.0(HR 2.59;95%CI 1.02-6.58;95%CI 1.11-3.01;95%CI 1.24-5.51;95%CI 3.08-16.4;

要点

  • 多因素分析证实新辅助治疗后LMR<3.0是独立不良预后因素(HR 2.59;95%CI 1.02-6.58)。
  • T4、淋巴结阳性及未完成辅助治疗亦为独立不良预后因素。

核心结论

  • 新辅助治疗后低淋巴细胞单核细胞比值对交界可切除胰腺癌患者具有预后价值,可能有助于治疗策略分层。

研究设计与样本

  • 回顾性研究,纳入2010至2016年间67例接受新辅助治疗后行胰腺切除的交界可切除胰腺癌患者,并与58例直接手术者比较。
  • 采用单因素和多因素分析评估中性粒细胞淋巴细胞比值、血小板淋巴细胞比值、淋巴细胞单核细胞比值及预后营养指数与生存的关联。

主要发现

  • 单因素分析显示新辅助治疗后中性粒细胞淋巴细胞比值、淋巴细胞单核细胞比值及预后营养指数与生存显著相关。

关键数值与推荐

  • 新辅助治疗后中性粒细胞淋巴细胞比值、淋巴细胞单核细胞比值及预后营养指数的最佳截断值分别为2.5、3.0和45。

临床怎么用

  • 对于交界可切除胰腺癌患者,新辅助治疗后检测淋巴细胞单核细胞比值可能辅助术前预后评估和治疗策略分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of systemic immune inflammatory markers to predict survival in patients receiving neoadjuvant therapy for borderline resectable pancreatic cancer has not been sufficiently investigated. This study aims to evaluate whether systemic immune inflammatory markers after neoadjuvant therapy followed by pancreatectomy become preoperative prognostic factors to predict survival in patients with borderline resectable pancreatic cancer. METHODS: We retrospectively reviewed 67 borderline resectable pancreatic cancer patients receiving neoadjuvant therapy and 58 borderline resectable pancreatic cancer patients undergoing upfront surgery between 2010 and 2016. The association between survival and systemic immune inflammatory markers was evaluated by univariate and multivariate analysis. The neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and prognostic nutrition index were assessed as systemic immune inflammatory markers. RESULTS: In univariate analysis, the postneoadjuvant neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and prognostic nutrition index are significantly associated with survival as systemic immune inflammatory markers. The optimal cutoff value of the postneoadjuvant neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and prognostic nutrition index were 2.5, 3.0, and 45, respectively. Patients with a lymphocyte-to-monocyte ratio <3.0 had significantly poor survival compared with those who had a lymphocyte-to-monocyte ratio ≥3.0 (14.9 months vs 31.7 months, P = .006). The multivariate analysis identified the following as predictors of poor prognosis: postneoadjuvant lymphocyte-to-monocyte ratio <3.0 (HR 2.59; 95% CI 1.02-6.58; P = .045), T4 (HR 1.82; 95% CI 1.11-3.01; P = .029), lymph node status (HR 2.62; 95% CI 1.24-5.51; P = .012), and no completion of adjuvant therapy (HR 7.09; 95% CI 3.08-16.4; P < .001). CONCLUSION: A low lymphocyte-to-monocyte ratio after neoadjuvant therapy is useful prognostic information for patients with borderline resectable pancreatic cancer. This result might indicate a potential role of lymphocyte-to-monocyte ratios in stratification of treatment strategy in borderline resectable pancreatic cancer patients.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Kawai M, Hirono S, Okada KI, et al. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. Surgery. 2019. PMID: 30765142. doi:10.1016/j.surg.2018.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。